Medexus Pharmaceuticals Inc (TSE:MDP)
TSX:MDP
Want to see TSE:MDP full AI Analyst Report?
MDP Stock Chart & Stats
C$3.97
C$0.09(2.60%)
At close: 4:00 PM EST
C$3.97
C$0.09(2.60%)
Day’s Range― - ―
52-Week RangeC$2.47 - C$4.17
Previous CloseN/A
Volume43.25K
Average Volume (3M)46.68K
Market Cap
C$130.17M
Enterprise ValueC$101.22M
Total Cash (Recent Filing)C$14.97M
Total Debt (Recent Filing)C$25.35M
Price to Earnings (P/E)―
Beta0.90
Next Earnings
Jun 30, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding32,300,380
10 Day Avg. Volume30,861
30 Day Avg. Volume46,683
Financial Highlights & Ratios
PEG Ratio1.50
Price to Book (P/B)1.19
Price to Sales (P/S)0.32
P/FCF Ratio1.95
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.26
Revenue Forecast (FY)C$114.60M
Bulls Say, Bears Say
Bulls Say
Earnings ConsistencyAnalyst notes reported results were broadly in line with estimates, supporting earnings predictability that could stabilize the stock.
Growth FoundationsAnalyst states good groundwork is being laid for future growth through strategic initiatives that could expand revenue potential.
Product RecoveryRasuvo is set to rebound, which could boost product revenues and improve overall sales momentum.
Bears Say
Channel Inventory HeadwindsGrafapex product revenues were lighter than expected because of channel inventory management, creating near-term revenue pressure.
Elevated Risk ProfileThe stock is classified as above-average risk, reflecting higher volatility and potential downside for risk-sensitive investors.
Usage Versus Reported RevenueGrafapex flat revenues mask underlying usage momentum, creating a disconnect that could delay visible sales improvement.
Medexus Pharmaceuticals Inc News
MDP FAQ
What was Medexus Pharmaceuticals Inc’s price range in the past 12 months?
Medexus Pharmaceuticals Inc lowest stock price was C$2.47 and its highest was C$4.17 in the past 12 months.
What is Medexus Pharmaceuticals Inc’s market cap?
Medexus Pharmaceuticals Inc’s market cap is C$130.17M.
When is Medexus Pharmaceuticals Inc’s upcoming earnings report date?
Medexus Pharmaceuticals Inc’s upcoming earnings report date is Jun 30, 2026 which is in 19 days.
How were Medexus Pharmaceuticals Inc’s earnings last quarter?
Medexus Pharmaceuticals Inc released its earnings results on Feb 11, 2026. The company reported C$0 earnings per share for the quarter, beating the consensus estimate of -C$0.032 by C$0.032.
Is Medexus Pharmaceuticals Inc overvalued?
According to Wall Street analysts Medexus Pharmaceuticals Inc’s price is currently Overvalued.
Does Medexus Pharmaceuticals Inc pay dividends?
Medexus Pharmaceuticals Inc does not currently pay dividends.
What is Medexus Pharmaceuticals Inc’s EPS estimate?
Medexus Pharmaceuticals Inc’s EPS estimate is -0.01.
How many shares outstanding does Medexus Pharmaceuticals Inc have?
Medexus Pharmaceuticals Inc has 32,300,380 shares outstanding.
What happened to Medexus Pharmaceuticals Inc’s price movement after its last earnings report?
Medexus Pharmaceuticals Inc reported an EPS of C$0 in its last earnings report, beating expectations of -C$0.032. Following the earnings report the stock price went down -2.491%.
Which hedge fund is a major shareholder of Medexus Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in TSE:MDP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Medexus Pharmaceuticals Inc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
3.84%
12-Months-Change
Fundamentals
Return on Equity
-0.52%
Trailing 12-Months
Asset Growth
1.19%
Trailing 12-Months
Company Description
Medexus Pharmaceuticals Inc
Medexus Pharmaceuticals Inc. operates as a specialized pharmaceutical company, conducting its business across Canada and the United States. The firm's strategic focus encompasses critical therapeutic domains such as oncology, hematology, rheumatology, autoimmune disorders, and allergy treatments. Among its principal offerings are Rasuvo and Metoject, which are methotrexate formulations designed for managing rheumatoid arthritis and various autoimmune conditions. Medexus also provides IXINITY, an intravenous recombinant factor IX therapeutic specifically for patients aged 12 and older suffering from Hemophilia B, along with Rupall, a prescription medication for allergy relief. The company's broader product portfolio includes Treosulfan, a bifunctional alkylating agent utilized in allogeneic hematopoietic stem cell transplantation; Trispan, an injectable suspension containing triamcinolone hexacetonide; and Gleolan, an optical imaging agent indicated for individuals presenting with glioma symptoms. Initially known as Pediapharm Inc., the company rebranded to Medexus Pharmaceuticals Inc. in December 2018. Its corporate headquarters are located in Bolton, Canada.
Technical Analysis
Options Prices
Currently, No data available
---